Quick answer
Stem cell therapy may modestly reduce pain and improve function in some older adults with knee osteoarthritis, but it has not been proven to restore mobility in general. A 2025 review of eight randomized trials (467 patients) estimated that only about one-third of the improvement after mesenchymal stem cell injections was due to the cells themselves, and rated the evidence low certainty. For age-related frailty, a phase 2b trial in 150 adults aged 70 to 85 missed its main walking-test goal. Exercise, strength training and physiotherapy remain the foundation, and stem cell therapy is best seen as an investigational add-on.
Key facts at a glance
- Best-studied use: knee osteoarthritis, injected into the joint.
- Typical result in trials: small to moderate pain and function gains, with a large placebo-type effect.
- Frailty and muscle loss: early research only; no approved stem cell treatment.
- Safety: early trials report few serious events, but outcomes depend heavily on the clinic and the product.
- Not a substitute for strength and balance training, which improves mobility in older adults on its own.
Why does mobility decline with age?
Mobility declines with age because several problems usually overlap: worn joints, loss of muscle, weaker balance and nerve or spine disease. Knowing which one is limiting you matters, because stem cell research targets some of these far more than others.
- Osteoarthritis (knee, hip): cartilage thins and the joint becomes painful and stiff, so walking, stairs and getting up from a chair become harder.
- Sarcopenia: age-related loss of muscle mass and strength, which slows walking and raises the risk of falls.
- Frailty: a broader state of reduced reserve, with weakness, slow walking and fatigue.
- Spine conditions: disc degeneration and spinal stenosis can cause back pain, leg pain and numbness that limit walking distance.
- Neurological and balance problems: conditions such as Parkinson’s disease, stroke, neuropathy and cerebral atrophy affect movement control.
These causes respond very differently to treatment. Viezec’s guide for elderly patients considering stem cell therapy and its article on regenerative therapies for an active lifestyle after 50 cover this in more depth.
Which mobility problems is stem cell therapy used for?
Stem cell therapy is studied for several causes of reduced mobility, but the strength of evidence differs a lot between them. The table shows what is researched and what is realistic to expect.
| Mobility problem | What is studied | Strength of evidence | Realistic expectation |
|---|---|---|---|
| Knee osteoarthritis | Mesenchymal stem cells injected into the joint | Strongest: multiple randomized trials, though quality is mixed | Modest pain relief and better function in some patients, not regrown cartilage you can rely on |
| Hip osteoarthritis | Intra-articular cell injections | Smaller, earlier studies | Possible symptom relief; benefit is less certain than in the knee |
| Back pain from disc degeneration, spinal stenosis | Disc or epidural injections of cells | Early-stage studies | Possible pain reduction in selected patients; not a proven fix for nerve compression |
| Frailty and sarcopenia | Intravenous mesenchymal cells | Phase 2 trials with mixed results | Experimental; no approved cell treatment for muscle loss |
| Parkinson’s disease, stroke, other neurological causes | Cell therapy for movement and recovery | Mostly early trials | Investigational; supportive rehabilitation remains essential |
If your main problem is a worn knee or hip, read Viezec’s pages on stem cell therapy for knee osteoarthritis, hip osteoarthritis, back pain and spinal stenosis. For age-related slowing in general, see non-surgical stem cell therapy for senior mobility.
What does the research say about stem cells and mobility in older adults?
The research shows a real but modest signal in knee osteoarthritis and no proven benefit yet for frailty or general mobility. Three findings matter most.
- Knee osteoarthritis, placebo effect: A systematic review of eight randomized trials (467 patients) found that contextual (placebo-related) effects explained about 63% of pain reduction and 61% of functional improvement at 6 months. The authors estimated that roughly one-third of the improvement came from the cells, called the benefit “modest”, and rated the certainty of evidence as low (Frontiers in Medicine, 2025).
- Frailty, walking test: The phase 2b trial of Lomecel-B enrolled 150 adults aged 70 to 85 with mild to moderate frailty. After a single infusion, none of the four doses showed a statistically significant placebo-adjusted gain on the six-minute walk test at day 180, so the primary endpoint was missed. The 200-million-cell group came closest, at about 41 metres (p = 0.0635) (BioSpace, 2021).
- Frailty, trial design: The same program’s earlier phase 2 study (30 frail participants) reported no treatment-emergent serious adverse events, and its authors acknowledged limits including small size and narrow inclusion criteria (Journal of Frailty & Aging).
What does the exercise evidence show for comparison?
Supervised exercise has stronger proof for preserving mobility. In the LIFE study of more than 1,600 inactive adults aged 70 to 89, a structured program of walking, leg strength, balance and flexibility work cut the risk of major mobility disability by 18% over an average of 2.6 years (NIH).
Is stem cell therapy for orthopedic conditions approved?
In the United States, no. The FDA states that regenerative medicine therapies have not been approved for any orthopedic condition such as osteoarthritis, and that stem cell, Wharton’s jelly and exosome products offered outside a regulated trial may be unapproved (FDA). Check the rules in your own country before you decide.
For Viezec’s own discussion of results, see efficacy of stem cell therapy in alleviating knee pain, how long stem cell injections last for knee pain and stem cell success rate.
How does stem cell therapy compare with other ways to improve mobility?
Stem cell therapy ranks as an optional, investigational choice after the well-proven basics. Here is how common options compare for an older adult with joint-related mobility loss.
| Option | Best for | Evidence and cost level | Main downsides |
|---|---|---|---|
| Exercise, strength and balance training | Almost everyone; the foundation of mobility care | Strongest evidence; low cost | Needs consistency and often supervision |
| Physiotherapy and weight management | Joint pain, stiffness, weak muscles | Strong evidence; low to moderate cost | Gradual results |
| Pain medicines and steroid injections | Short-term pain control | Well established; low cost | Temporary; side effects with long-term use |
| Hyaluronic acid or PRP injections | Mild to moderate knee osteoarthritis | Mixed evidence; moderate cost | Variable response; repeat injections |
| Stem cell injections | Selected knee or hip osteoarthritis when other options have not worked | Early to moderate evidence; higher cost; investigational | Uncertain benefit; quality varies by clinic |
| Joint replacement surgery | Advanced joint damage with severe pain | Strong evidence; high cost | Surgical and anaesthetic risk, rehabilitation |
To compare Viezec’s views, see stem cell therapy vs PRP therapy, stem cell therapy vs surgery, PRP therapy for knee osteoarthritis and hip replacement alternatives. Physiotherapy after treatment is covered in the importance of physical therapy following stem cell procedures.
Is stem cell therapy safe for older adults?
In regulated studies, serious side effects have been uncommon, but safety depends on the product, the clinic and your own health. Older adults often take blood thinners, have heart, kidney or diabetes problems, and heal more slowly, so a medical review comes first.
What are the possible risks?
- Pain, swelling or infection at the collection or injection site.
- Temporary joint flare-up or inflammation after a joint injection.
- Unwanted immune or inflammatory reactions.
- Contaminated or poorly tested products, which is the main danger at unregulated clinics. The FDA lists infections, tumour formation and neurological events among harms reported from unapproved products (FDA).
- Spending money on a treatment that does not help while skipping care that does.
How to lower the risk
- Get a joint exam and imaging (X-ray or MRI) from an orthopedic or rehabilitation doctor first.
- Share your full medicine list, especially blood thinners, and your medical history.
- Ask for the cell source, how cells are processed and tested, and the written risk list.
- Avoid clinics that promise cartilage regrowth, a cure or guaranteed results.
- Report any serious reaction to your doctor and the local regulator.
Read Viezec’s pages on safety and adverse effects of stem cell treatment, stem cell therapy safety, quality control tests and are mesenchymal stem cells safe.
Who may be a candidate, and how can you get the best result?
The people most likely to be considered are older adults with knee or hip osteoarthritis that is limiting daily life and has not improved enough with exercise, physiotherapy and medicines. Whether you suit it is a decision for an orthopedic or rehabilitation specialist after examining you.
Who may be considered
- Adults with mild to moderate joint wear who want to delay or avoid surgery.
- People whose main problem is pain and stiffness in one or two joints.
- Those who can commit to rehabilitation after treatment.
Who should be cautious or look at other options first
- People with very advanced joint damage, where replacement surgery may work better.
- Those with active infection, uncontrolled diabetes, or serious heart, kidney or blood conditions.
- Anyone whose mobility problem is mainly muscle loss or balance, where supervised training is the proven treatment.
How soon will I notice a difference, and how long can it last?
Responses vary, and the evidence does not support a fixed timeline. Viezec discusses expectations in how long stem cell therapy takes to work and how long it lasts.
To discuss your reports with a specialist, contact the Viezec team. International patients can start with the international patient flow chart.
Frequently asked questions
Sometimes, modestly. In knee osteoarthritis, trials report less pain and better function in some patients, but a 2025 review estimated that only about one-third of the gain came from the cells themselves. For frailty and muscle loss, benefit is unproven.
It may help some seniors with mild to moderate knee osteoarthritis, mainly by reducing pain and improving function. Results vary, the evidence is rated low certainty, and exercise and physiotherapy should continue alongside it.
Symptom relief is reported far more consistently than reliable cartilage regrowth. Do not accept a promise of “new cartilage” from any clinic.
There is no single age cut-off. Your joint condition, heart, kidney and blood health, medicines and ability to do rehabilitation matter more than your age, and a specialist should assess them.
There is no fixed answer. Trials mostly follow patients for 6 to 12 months, and long-term benefit is less well established. See how long stem cell injections last for knee pain.
In the United States, the FDA says no regenerative medicine therapy is approved for any orthopedic condition such as osteoarthritis, and products offered outside a regulated trial may be unapproved. Rules differ by country, so ask any clinic how it is regulated where you will be treated.
Not yet. The phase 2b trial of Lomecel-B in adults aged 70 to 85 did not reach statistical significance on its main walking-test endpoint, so it remains research.
A combined program of walking, leg strength, balance and flexibility. In the LIFE study it reduced the risk of major mobility disability by 18%.
Ask which cells are used and how they are tested, whether it is a registered trial, what the written risks are, who examines you before and after, and what results the clinic can document. Avoid any guarantee of cure.
Conditions We Treat
Explore stem cell treatment options in India
